The Biotech Startups Podcast

Part 1 of 3. My guest for this week’s episode is Quin Wills, CSO and Co-Founder of Ochre Bio, a pioneering biotechnology company developing RNA therapies for chronic liver diseases. Using a combination of genomic deep phenotyping, precision RNA medicine, and testing in live human donor livers, Ochre is developing therapies for liver health challenges ranging from increasing donor liver supply to reducing cirrhosis complications.

Part 3 of 3. My guest for this week’s episode is Grant Aarons, Co-Founder and CEO of FabricNano, a London-based biotech whose mission is to transform industrial chemical processes using cell-free biomanufacturing. FabricNano empowers users with the world's most advanced, flexible, and easily scalable biocatalyst platform, providing highly stable and performant biocatalysts to enable profitable production of sustainable and biobased chemicals. Their approach starts with novel immobilization engineering for enzyme stabilization, followed by budget-conscious protein engineering and process engineering to reach their clients' targets for commercialization of their new biochemical production process.

Part 2 of 3. My guest for this week’s episode is Grant Aarons, Co-Founder and CEO of FabricNano, a London-based biotech whose mission is to transform industrial chemical processes using cell-free biomanufacturing. FabricNano empowers users with the world's most advanced, flexible, and easily scalable biocatalyst platform, providing highly stable and performant biocatalysts to enable profitable production of sustainable and biobased chemicals. Their approach starts with novel immobilization engineering for enzyme stabilization, followed by budget-conscious protein engineering and process engineering to reach their clients' targets for commercialization of their new biochemical production process.

Part 1 of 3. My guest for this week’s episode is Grant Aarons, Co-Founder and CEO of FabricNano, a London-based biotech whose mission is to transform industrial chemical processes using cell-free biomanufacturing. FabricNano empowers users with the world's most advanced, flexible, and easily scalable biocatalyst platform. With clients ranging from startups to multinationals like Sumitomo Chemical Company, FabricNano provides highly stable and performant biocatalysts to enable profitable production of sustainable and biobased chemicals.

Part 3 of 3. My guest for this week’s episode is Bryan Dechairo, President, CEO, and Director at Sherlock Biosciences, an innovative biotech company that is enabling the democratization and decentralization of diagnostic testing to personalize healthcare and make an impact on global health.

Part 2 of 3. My guest for this week’s episode is Bryan Dechairo, President, CEO, and Director at Sherlock Biosciences, an innovative biotech company that is enabling the democratization and decentralization of diagnostic testing to personalize healthcare and make an impact on global health.

Part 1 of 3. My guest for this week’s episode is Bryan Dechairo, President, CEO, and Director at Sherlock Biosciences, an innovative biotech company that is enabling the democratization and decentralization of diagnostic testing to personalize healthcare and make an impact on global health. The Sherlock team and founders include engineering biology pioneers with world-leading expertise in CRISPR and synthetic biology, diagnostic industry veterans, and disease area authorities.

Part 3 of 3. My guest for this week’s episode is Terry Lo, President and CEO of Vizgen. Vizgen is developing and commercializing the next generation of genomics tools to expand on the capabilities of spatially resolved transcriptomics. Terry is a pioneer in the emerging Spatial Biology market, with a proven track record of driving exceptional growth across global life science organizations, including Bristol-Myers Squibb, Roche, Hologic, and PerkinElmer. In addition to his two decades of experience scaling and building multinational biopharma and diagnostic groups, he is also an expert in developing business strategies for novel, innovative products.

Part 2 of 3. My guest for this week’s episode is Terry Lo, President and CEO of Vizgen. Vizgen is developing and commercializing the next generation of genomics tools to expand on the capabilities of spatially resolved transcriptomic. Terry is a pioneer in the emerging Spatial Biology market, with a proven track record of driving exceptional growth across global life science organizations, including Bristol-Myers Squibb, Roche, Hologic, and PerkinElmer. In addition to his two decades of experience scaling and building multinational biopharma and diagnostic groups, he is also an expert in developing business strategies for novel, innovative products.

Part 1 of 3. My guest for this week’s episode is Terry Lo, President and CEO of Vizgen. Vizgen is developing and commercializing the next generation of genomics tools to expand on the capabilities of spatially resolved transcriptomics. Vizgen’s technology will aid the acceleration of biological research and discovery to advance human health

Part 3 of 3. My guest for this week’s episode is Mike Stadnisky, Managing Director of Thielsen Capital. Thielsen Capital is a seed-stage financing syndicate network bringing together life science investors, operators, and innovators to drive exceptional outcomes for founding teams, investors, and science.

Part 2 of 3. My guest for this week’s episode is Mike Stadnisky, Managing Director of Thielsen Capital. Thielsen Capital is a seed-stage financing syndicate network bringing together life science investors, operators, and innovators to drive exceptional outcomes for founding teams, investors, and science. Before Thielsen, Mike was the CEO of Phitonex, which Thermo Fisher acquired. He was also VP & GM of Informatics at BD Life Sciences and was the CEO of FlowJo before its acquisition by BD. He has also taught at MIT Sloan, authored 10 patents, and won the 2019 International Society for the Advancement of Cytometry Innovation Award.

Part 1 of 3. My guest for this week’s episode is Mike Stadnisky, Managing Director of Thielsen Capital. Thielsen Capital is a seed-stage financing syndicate network bringing together life science investors, operators, and innovators to drive exceptional outcomes for founding teams, investors, and science. Before Thielsen, Mike was the CEO of Phitonex, which Thermo Fisher acquired. He was also VP & GM of Informatics at BD Life Sciences and was the CEO of FlowJo before its acquisition by BD. He has also taught at MIT Sloan, authored 10 patents, and won the 2019 International Society for the Advancement of Cytometry Innovation Award.

Part 3 of 3. My guest for this week’s episode is Martin Brenner, CEO and CSO of iBio. iBio uses its AI drug discovery platform to tackle complex and challenging drug targets to develop safer and more effective immunotherapies for difficult-to-treat cancers. Rather than leaving drug discovery to chance, iBio guides the process using artificial intelligence, making therapeutic development smarter, faster, and more precise.

Part 2 of 3. My guest for this week’s episode is Martin Brenner, CEO and CSO of iBio. iBio uses its AI drug discovery platform to tackle complex and challenging drug targets to develop safer and more effective immunotherapies for difficult-to-treat cancers. Rather than leaving drug discovery to chance, iBio guides the process using artificial intelligence, making therapeutic development smarter, faster, and more precise.

Part 1 of 3. My guest for this week’s episode is Martin Brenner, CEO and CSO of iBio. iBio uses its AI drug discovery platform to tackle complex and challenging drug targets to develop safer and more effective immunotherapies for difficult-to-treat cancers. Rather than leaving drug discovery to chance, iBio guides the process using artificial intelligence, making therapeutic development smarter, faster, and more precise.

Part 3 of 3. My guest for this week’s episode is Jeff Kim, co-founder and CEO of Slingshot Biosciences. Slingshot designs and manufactures synthetic cells for R&D, clinical diagnostics, and engineered cell therapies, aiming to overcome supply chain and cost barriers that restrict access to advanced diagnostics and therapeutics.

Part 2 of 3. My guest for this week’s episode is Jeff Kim, co-founder and CEO of Slingshot Biosciences. Slingshot designs and manufactures synthetic cells for R&D, clinical diagnostics, and engineered cell therapies, aiming to overcome supply chain and cost barriers that restrict access to advanced diagnostics and therapeutics.

My guest for this week’s episode is Jeff Kim, co-founder and CEO of Slingshot Biosciences. Slingshot designs and manufactures synthetic cells for R&D, clinical diagnostics, and engineered cell therapies, aiming to overcome supply chain and cost barriers that restrict access to advanced diagnostics and therapeutics.

Part 3 of 3. My guest for this week’s episode is Stephanie Sirota, Partner, and Chief Business Officer at RTW Investments, a full lifecycle life sciences investment firm dedicated to solving the most challenging unmet patient needs. Stephanie is a seasoned expert and leader in business development, strategic partnerships, communications, and investor relations.